Parkinson’s Disease - Pipeline Review, H2 2017

Parkinson’s Disease - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Parkinson’s Disease - Pipeline Review, H2 2017, provides an overview of the Parkinson’s Disease (Central Nervous System) pipeline landscape.

Parkinson’s disease is a neurodegenerative disorder characterized by movement dysfunctions. It causes involuntary shaking, stiffness and impaired locomotory functions. Age, genetic factors, head trauma, environmental factors, hormonal changes, etc are predisposing factors for Parkinson’s disease. Parkinson’s disease results in abnormal functioning or death of neurons. The neurons are responsible for the synthesis of neurotransmitter dopamine which is further responsible for the transmission of signals. The effect on the neurons blocks effective neurotransmission and may lead to eventual decline in movement and coordination.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Parkinson’s Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Parkinson’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinson’s Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson’s Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 8, 41, 42, 4, 190, 50 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 46 and 13 molecules, respectively.

Parkinson’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinson’s Disease (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Parkinson’s Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Parkinson’s Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Parkinson’s Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews the latest news related to pipeline therapeutics for Parkinson’s Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Parkinson’s Disease (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Parkinson’s Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction 8
Parkinson’s Disease - Overview 9
Parkinson’s Disease - Therapeutics Development 10
Parkinson’s Disease - Therapeutics Assessment 52
Parkinson’s Disease - Companies Involved in Therapeutics Development 72
Parkinson’s Disease - Drug Profiles 146
Parkinson’s Disease - Dormant Projects 766
Parkinson’s Disease - Discontinued Products 781
Parkinson’s Disease - Product Development Milestones 783
Appendix 791

List Of Tables

Number of Products under Development for Parkinson’s Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Products under Development by Companies, H2 2017 (Contd..15), H2 2017
Products under Development by Companies, H2 2017 (Contd..16), H2 2017
Products under Development by Companies, H2 2017 (Contd..17), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Parkinson’s Disease - Pipeline by 2-BBB Medicines BV, H2 2017
Parkinson’s Disease - Pipeline by 4P Therapeutics LLC, H2 2017
Parkinson’s Disease - Pipeline by AbbVie Inc, H2 2017
Parkinson’s Disease - Pipeline by AC Immune SA, H2 2017
Parkinson’s Disease - Pipeline by Acorda Therapeutics Inc, H2 2017
Parkinson’s Disease - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
Parkinson’s Disease - Pipeline by Addex Therapeutics Ltd, H2 2017
Parkinson’s Disease - Pipeline by Aeolus Pharmaceuticals Inc, H2 2017
Parkinson’s Disease - Pipeline by AFFiRiS AG, H2 2017
Parkinson’s Disease - Pipeline by Amabiotics SAS, H2 2017
Parkinson’s Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Parkinson’s Disease - Pipeline by American Gene Technologies International Inc, H2 2017
Parkinson’s Disease - Pipeline by Anavex Life Sciences Corp, H2 2017
Parkinson’s Disease - Pipeline by Antoxis Ltd, H2 2017
Parkinson’s Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
Parkinson’s Disease - Pipeline by APeT Holding BV, H2 2017
Parkinson’s Disease - Pipeline by ApoPharma Inc, H2 2017
Parkinson’s Disease - Pipeline by Aposense Ltd, H2 2017

List Of Figures

Number of Products under Development for Parkinson’s Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Fill The Form For Sample Request

There is no Reviews available